doi:10.16597/j.cnki.issn.1002-154x.2022.07.007
索拉非尼的研究
宋梅 李慧玲∗
(佳木斯大学附属第一医院,黑龙江 佳木斯 154003)
A Study on the Sorafenib
Song Mei1; Li Huiling2∗;
(The First Affiliated Hospital of Jiamusi University, Heilongjiang Jiamusi 154003)
摘要:
索拉非尼是美国拜耳股份有限公司的专利药,2005 年美国 FDA 批准用于治疗肝细胞癌(HCC),2006 年欧洲药品管理局(EMA)批准用于治疗肾细胞癌( RCC) 晚期。 索拉非尼既可以作用于血管内皮细胞生长因子受体 (VEGFR),抑制新生血管的形成和阻断肿瘤细胞的营养供应,也可以通过阻断细胞信号传导通路以达到遏制肿瘤细胞生长的目的。 本文主要综述了索拉非尼的基本化学信息、化学合成、医学应用以及联合纳米技术应用的展望。
关键词：索拉非尼 肝细胞癌 肾细胞癌 纳米技术
Abstract：
Sorafenib is a patented drug of Bayer AG. It was approved by the US FDA for the treatment of hepatocellular carcinoma (HCC) in 2005 and the European Medicines Agency (EMA) for the treatment of advanced renal cell carcinoma (RCC) in 2006. Sorafenib can not only act on vascular endothelial cell growth factor receptor (VEGFR), inhibit the formation of new blood vessels and block the nutritional supply of tumor cells, but also inhibit the growth of tumor cells by blocking cell signal transduction pathways. In this paper, the basic chemical information, chemical synthesis, medical application and the prospect of nanotechnology of Sorafenib are reviewed.
Keywords：Sorafenib; hepatocellular carcinoma; renal cell carcinoma; nanotechnology;